FL-BIEDERMANN-MOTECH
21.9.2021 12:02:07 CEST | Business Wire | Press release
Biedermann Motech, the company that developed the world’s first polyaxial pedicle screw (MOSS® System) and pioneer in the spinal market for more than 35 years, today announced that its MOSS VRS® Pedicle Screw Platform, the most advanced system on the market today, is now available as a fully modular solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005274/en/
The MOSS VRS System features Next Generation Pedicle Screw Technology™, which allows the surgeon to lock the polyaxial angle of the pedicle screw at any angle, at any time during surgery. This provides surgeons unmatched intraoperative real-time options using a single, highly functional implant.
In contrast to traditional pedicle screw systems, which include a wide range of different screw types, the MOSS VRS Pedicle Screw can be locked and unlocked as and when required by the surgeon during complex correction and reconstruction maneuvers.
By adding MOSS Modularity™ to this unique functionality, surgeons now will have the option to attach the modular MOSS VRS tulip heads after the pedicle screw shafts have been placed, allowing even more advanced and versatile surgical techniques.
”Over 30 years after the introduction of the MOSS System, the world’s first polyaxial pedicle screw, we are excited to continue to lead the advancement of posterior screw systems with the further expansion of our MOSS VRS platform,” said Markku Biedermann, President & CEO of Biedermann Motech, Inc.
The unique and proprietary technologies of the MOSS VRS System are licensed from Biedermann Technologies GmbH & Co. KG, a company which holds a broad and extensive patent and technology portfolio, and are exclusively available through Biedermann Motech.
Biedermann Motech will showcase the MOSS VRS System at the upcoming North American Spine Society (NASS) Annual Meeting in Boston, MA, September 22-24, 2021 at booth #2349.
About Biedermann Motech
Biedermann Motech is a mid-sized, family owned group of companies with headquarters in Germany (Villingen-Schwenningen) and the USA (Miami) whose roots go back to 1916. Since then, the focus has been on working in synergy with world-class surgeons to solve significant clinical challenges through the development of next generation technologies. The core competency is the development, production, and distribution of innovative implants and instruments for spinal and extremity surgery. Biedermann Motech researches, develops, manufactures, and distributes high-quality implant systems in collaboration with healthcare professionals, technology partners, scientific institutions, and specialized companies with the goal of achieving improved clinical outcomes. For more information about Biedermann Motech, please visit: www.biedermann.com .
Follow us:
LinkedIn: https://www.linkedin.com/company/biedermannmotech
Instagram: https://www.instagram.com/biedermannmotech/
About Biedermann Technologies
Biedermann Technologies GmbH & Co. KG (www.biedermann-technologies.com ) is a privately held company based in Germany (Donaueschingen) and is the owner and guardian of a substantial patent and technology portfolio for specialized orthopedic markets. For the last 25 years, Biedermann Technologies has successfully licensed numerous patents and related technologies to several key players in the orthopedic and neurosurgical field.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005274/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release
Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom